Business
Ionis' antisense therapies to be featured at the American Heart Association (AHA) Scientific Sessions 2021
- New data to be presented from multiple ascending dose study for Ionis' novel antisense medicine targeting PCSK9 - Data on the effect of olezarsen on a
About this update from Ionis Pharmaceuticals, Inc.
[{"type":"text","content":"- New data to be presented from multiple ascending dose study for Ionis' novel antisense medicine targeting PCSK9\n - Data on the effect of olezarsen on a variety of lipoprotein fractions in patients with hypertriglyceridemia to be presented\n - Ionis to host symposium on lessening the disproportionate impact of transthyretin amyloid cardiomyopathy (ATTR-CM) on Black and African American patients\n\n\nCARLSBAD, Calif., Nov. 12, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, announced today the upcoming presentations of clinical and non-clinical data from its cardiovascular pipeline, including several of its investigational antisense medicines for cardiovascular disease, at the American Heart Association (AHA) Scientific Sessions, to be held virtually Nov. 13-15, 2021.\n\n \n \n \n \n \n \n\n \nNew data from the Phase 1 multiple ascending dose study for ION449 (also known as AZD8233) will be featured in an oral presentation. ION449, an investigational antisense medicine that uses Ionis' proprietary Ligand-Conjugated Antisense technology (LICA), is designed to reduce the production of PCSK9 and lower the plasma level of low-density lipoprotein-cholesterol (LDL-C) in patients who are at risk of cardiovascular disease due to high levels of LDL-C. Genetic studies have shown that individuals with life-long reduction of LDL-C due to reduced function of PCSK9 have substantially reduced risk of cardiovascular disease. Data to be presented include results from a study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending subcutaneous doses of ION449 in patients with dyslipidemia. ION449 is being developed by AstraZeneca as part of a collaboration between Ionis and AstraZeneca. \nIonis will also present data on the effect of olezarsen, formerly known as IONIS-APOCIII-LRx, on a variety of lipoprotein fractions measured by Nuclear Magnetic Resonance (NMR) in patients with cardiovascular disease and hypertriglyceridemia. The apolipoprotein C-III (apoC-III) protein is an independent cardiovascular risk factor that regulates triglyceride metabolism in the blood. Olezarsen is designed to inhibit the production of apoC-III in patients who are at risk for cardiovascular disease due to elevated triglyceride levels. Olezarsen is an investigational anti...